Later, β3-AR antagonism reduced melanoma growth in vivo by increasing the NK and CD8 cell numbers as well as their cytotoxicity in the TME through the regulation of Treg and MDSC sub-populations [156]. The gene discussed is ADRB3; the disease is melanoma.